Movement Alert｜ASYMCHEM Rises 3.13% in Regular Trading, Board Approves Charter Amendment as CRO Sector Momentum Continues

Market Focus09-29

On September 29, ASYMCHEM rose 3.13% in regular trading, trading at 163.7 HKD/share, with turnover of 13.3569 million HKD.

On the news front, the company held its fifth board of directors fifteenth meeting on September 28, unanimously approving a charter amendment proposal. The revision reflects the completion of registration for 2,436,500 restricted shares under its A-share restricted stock incentive plan, increasing registered capital from 360.66 million to 361.95 million yuan. Of these, 1,285,200 shares are newly issued and 1,151,300 shares were sourced from prior buybacks. A special shareholders meeting is scheduled for October 20 to formally ratify the amendment.

At the industry level, the CRO/CDMO sector continues to benefit from sustained high prosperity in innovative drugs. Brokerages have noted that domestic CXO companies posted H1 revenue and net profit growth of 24.5% and 52.7% respectively, with AI-driven drug development accelerating commercialization and further catalyzing sector momentum. ASYMCHEM itself reported H1 revenue of 3.607 billion yuan, up 13.13% year-over-year, and guided for full-year revenue growth of 19%-22%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120155686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120155686","market":"us","top_or_hot":-1,"title":"Movement Alert｜ASYMCHEM Rises 3.13% in Regular Trading, Board Approves Charter Amendment as CRO Sector Momentum Continues","media":"Market Focus","content":"<p><p>On September 29, ASYMCHEM rose 3.13% in regular trading, trading at 163.7 HKD/share, with turnover of 13.3569 million HKD.</p><p>On the news front, the company held its fifth board of directors fifteenth meeting on September 28, unanimously approving a charter amendment proposal. The revision reflects the completion of registration for 2,436,500 restricted shares under its A-share restricted stock incentive plan, increasing registered capital from 360.66 million to 361.95 million yuan. Of these, 1,285,200 shares are newly issued and 1,151,300 shares were sourced from prior buybacks. A special shareholders meeting is scheduled for October 20 to formally ratify the amendment.</p><p>At the industry level, the CRO/CDMO sector continues to benefit from sustained high prosperity in innovative drugs. Brokerages have noted that domestic CXO companies posted H1 revenue and net profit growth of 24.5% and 52.7% respectively, with AI-driven drug development accelerating commercialization and further catalyzing sector momentum. ASYMCHEM itself reported H1 revenue of 3.607 billion yuan, up 13.13% year-over-year, and guided for full-year revenue growth of 19%-22%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ASYMCHEM Rises 3.13% in Regular Trading, Board Approves Charter Amendment as CRO Sector Momentum Continues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ASYMCHEM Rises 3.13% in Regular Trading, Board Approves Charter Amendment as CRO Sector Momentum Continues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-29 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 29, ASYMCHEM rose 3.13% in regular trading, trading at 163.7 HKD/share, with turnover of 13.3569 million HKD.</p><p>On the news front, the company held its fifth board of directors fifteenth meeting on September 28, unanimously approving a charter amendment proposal. The revision reflects the completion of registration for 2,436,500 restricted shares under its A-share restricted stock incentive plan, increasing registered capital from 360.66 million to 361.95 million yuan. Of these, 1,285,200 shares are newly issued and 1,151,300 shares were sourced from prior buybacks. A special shareholders meeting is scheduled for October 20 to formally ratify the amendment.</p><p>At the industry level, the CRO/CDMO sector continues to benefit from sustained high prosperity in innovative drugs. Brokerages have noted that domestic CXO companies posted H1 revenue and net profit growth of 24.5% and 52.7% respectively, with AI-driven drug development accelerating commercialization and further catalyzing sector momentum. ASYMCHEM itself reported H1 revenue of 3.607 billion yuan, up 13.13% year-over-year, and guided for full-year revenue growth of 19%-22%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1120155686","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120155686","pubTimestamp":1790646104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 29, ASYMCHEM rose 3.13% in regular trading, trading at 163.7 HKD/share, with turnover of 13.3569 million HKD.On the news front, the company held its fifth board of directors fifteenth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英"},"translate_title":"走势提醒|凯莱英常规交易上涨 3.13%，CRO 行业势头持续，董事会批准章程修正案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1},"content_text":"On September 29, ASYMCHEM rose 3.13% in regular trading, trading at 163.7 HKD/share, with turnover of 13.3569 million HKD.On the news front, the company held its fifth board of directors fifteenth meeting on September 28, unanimously approving a charter amendment proposal. The revision reflects the completion of registration for 2,436,500 restricted shares under its A-share restricted stock incentive plan, increasing registered capital from 360.66 million to 361.95 million yuan. Of these, 1,285,200 shares are newly issued and 1,151,300 shares were sourced from prior buybacks. A special shareholders meeting is scheduled for October 20 to formally ratify the amendment.At the industry level, the CRO/CDMO sector continues to benefit from sustained high prosperity in innovative drugs. Brokerages have noted that domestic CXO companies posted H1 revenue and net profit growth of 24.5% and 52.7% respectively, with AI-driven drug development accelerating commercialization and further catalyzing sector momentum. ASYMCHEM itself reported H1 revenue of 3.607 billion yuan, up 13.13% year-over-year, and guided for full-year revenue growth of 19%-22%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120155686","isCrawlerRequest":true}